Hypha Labs, INC

Hypha Labs, Inc. announced a change in its independent registered public accounting firm, dismissing Fruci & Associates II, PLLC and engaging Astra Audit and Advisory, LLC, though the previous auditor had raised going concern doubts.

Hypha Labs, Inc. adopts a new code of conduct and business ethics while also formalizing a consulting agreement with its Chairman, President, CEO, CFO, and Secretary.

Hypha Labs, Inc. has amended its Articles of Incorporation to significantly increase the number of authorized common and preferred shares.

Hypha Labs, Inc. sold 1,000 shares of Series C Preferred Stock to its CEO, A. Stone Douglass, for $0.10 per share, granting him majority voting power to approve an increase in authorized common and preferred shares.

Hypha Labs, Inc., formerly Digipath, Inc., has officially changed its name following the sale of its testing business on February 20, 2024.

Digipath Inc. reports the resignation of its President, Todd Denkin, and the appointment of A. Stone Douglass as the new President and CEO, effective February 29, 2024.

Hypha Labs, Inc. details its strategic pivot from cannabis testing to mushroom bioreactor development, reporting a net loss for the quarter ended March 31, 2026.

Hypha Labs, Inc. shifts focus from cannabis testing to mushroom cultivation technology, reporting significant losses and a going concern doubt during its R&D phase.

Hypha Labs, Inc. reported a substantial net loss of $1.98 million for the six months ended March 31, 2025, as it transitions from cannabis testing to developing a mushroom accelerator, raising significant concerns about its ability to continue as a going concern.

Hypha Labs, formerly Digipath, reports its Q1 2025 results, highlighting its transition to bioreactor development and commercialization after selling its cannabis testing lab.

Hypha Labs, formerly Digipath, reports its Q3 2024 results, reflecting the sale of its Digipath Labs subsidiary and a shift in business focus.

Hypha Labs, formerly Digipath, reports its Q2 2024 results, highlighting the completion of the sale of its Digipath Labs assets and a shift in business focus.

Hypha Labs, Inc. reported a significant net loss and auditor's doubt about its ability to continue as a going concern, as it pivots from cannabis testing to developing a home mushroom accelerator.

Hypha Labs, formerly Digipath, transitions to developing mushroom bioreactors after selling its cannabis testing assets, but faces substantial doubt about its ability to continue as a going concern.

Digipath, Inc. has filed an amended annual report to correct a prior audit opinion and disclosed the pending sale of its cannabis testing lab for $2.3 million.

Digipath Inc. reports the planned sale of its cannabis testing lab and a strategic shift towards acquiring a new business in its annual 10-K filing.

Hypha Labs CEO, Douglass A Stone, received 6 million shares of common stock in two separate grants, one for services related to the sale of Digipath Labs, Inc. and the other for his appointment as CEO.

Hypha Labs intends to increase its authorized shares of common and preferred stock to enhance its financing and capital-raising capabilities.